Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma Expands U.S.-Based Manufacturing Capacity of Opaganib for COVID-19
RedHill adds two more manufacturing partners, both U.S.-based, for large-scale manufacturing of opaganib, in preparation for potential emergency use applications as early as Q1/2021   The new collaborations follow recently announced collaborations with European and Canadian manufacturers   U.S. ...
View HTML
Toggle Summary RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences
TEL AVIV, Israel and RALEIGH, N.C. , Nov. 23, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present and participate at the following virtual conferences in December: Evercore ISI 3 rd ...
View HTML
Toggle Summary RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First-Line Treatment of NTM Disease
RHB-204 is being evaluated as a first-line, stand-alone, oral treatment for pulmonary nontuberculous mycobacteria (NTM) disease - a rare condition with no FDA-approved first-line therapy   The Phase 3 study is expected to recruit up to 125 patients across approximately 40 U.S. ...
View HTML
Toggle Summary RedHill Announces Unanimous DSMB Recommendation to Continue Phase 2/3 COVID-19 Study with Opaganib
Pre-scheduled independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of the global Phase 2/3 study of orally administered opaganib in severe COVID-19 pneumonia   Enrollment in the 270-patient global Phase 2/3 COVID-19 study with opaganib is more than 50% complete   ...
View HTML
Toggle Summary RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleared by FDA for Phase 2/3 Study in Symptomatic COVID-19 Disease
FDA clears IND application for Phase 2/3 study with RedHill's second novel COVID-19 candidate, RHB-107 (upamostat), an orally administered novel serine protease inhibitor, with demonstrated antiviral and potential tissue-protective effects   The Phase 2/3 study is designed to evaluate ...
View HTML
Toggle Summary RedHill Biopharma Completes Enrollment for COVID-19 U.S. Phase 2 Study with Opaganib - Data Expected in the Coming Weeks
Enrollment completed in the U.S. Phase 2 study evaluating opaganib's safety and initial efficacy signal in 40 hospitalized patients with severe COVID-19 pneumonia   A parallel global Phase 2/3 study with orally administered opaganib for severe COVID-19 is approximately 50% enrolled - on track to ...
View HTML
Toggle Summary RedHill Biopharma to Present at German Equity Forum 2020
TEL AVIV, Israel and RALEIGH, N.C. , Nov. 13, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Guy Goldberg , RedHill’s Chief Business Officer, will present a corporate overview and host ...
View HTML
Toggle Summary RedHill Biopharma Provides Q3/2020 Results and Highlights, Including 300% Talicia Prescription Growth
Q3/2020 net revenues of approximately $21 million , with gross profit of $10.6 million , or approximately 51% , up from $6.7 million   and approximately 32% in Q2/2020 -- Strong growth for Talicia ®   with approximately 300 % quarter- over -quarter prescription growth   and rapid expansion of the ...
View HTML
Toggle Summary RedHill Biopharma to Host Third Quarter Financial Results and Business Highlights Webcast on November 12, 2020
TEL AVIV, Israel and RALEIGH, N.C. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will report its third-quarter 2020 financial results and business highlights on Thursday, ...
View HTML
Toggle Summary RedHill Biopharma Receives U.S. Patent Allowance Covering Opaganib and RHB-107 Combination
Notice of Allowance received for combination of RedHill’s novel orally-administered investigational drugs, opaganib and RHB-107, for treatment of solid tumor cancers; patent expected to extend IP protection until 2036 -- Combination of opaganib and RHB-107 demonstrated potent antitumor effect and ...
View HTML